Expert Analysis

HCV Management: Facing New Challenges

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

HCV Management: Facing New Challenges

Faculty:

Gary L. Davis, MD
Jean-Michel Pawlotsky, MD, PhD
Mitchell L. Shiffman, MD

CREDIT INFORMATION

Release Date: February 09, 2006

Expiration Date: February 08, 2007

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.9 Nursing contact hours

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the impact of sustained virologic response to interferon-based treatment in the subsequent development of hepatocellular carcinoma and death
Review the results of recent studies evaluating the use of peginterferon/ribavirin combinations, including higher than typical dosages, for treatment of previous nonresponders to HCV therapy
Evaluate the results of trials of drugs in development for treatment of HCV infection

Topics covered include:

E1/E2 Vaccine
HCV Protease Inhibitors and Other New Drugs
Immune Stimulators and Alternate Forms of Interferon
Treatment of Nonresponders and Relapsers
High-Dose Ribavirin for Reduced Relapse Rates
Genotype 1 Rapid Responders and Shorter Treatment
Natural History After SVR

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.